RxSight (RXST) Earnings Analysis

RxSight (RXST) has no confirmed upcoming earnings date. Last quarter (2026-02-25) it beat with EPS -0.22 USD vs -0.3347 USD est (+34.3%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -4.77.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does RXST next report earnings?

No confirmed upcoming earnings date is currently scheduled for RXST. This page updates as the calendar is published.

RXST earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-02-25-0.22 USD-0.3347 USD+34.3%Beat
2025-08-07-0.08 USD-0.1 USD+20%Beat
2024-11-07-0.16 USD-0.25 USD+36%Beat
2024-08-05-0.16 USD-0.22 USD+27.3%Beat

Beat rate: 4/4 (100%) over reported quarters with consensus data.

RXST valuation and analyst view

Trailing P/E-4.77
Trailing EPS-1.12906 USD
Price / book0.83
Dividend yield0.00%
Market cap0.22B
Analyst consensusHold (3 buy / 7 hold / 2 sell)
Avg price target8.75 USD

Related research pages

Frequently asked questions

When is RxSight (RXST)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for RXST. This page updates as the calendar is published.

Did RXST beat earnings last quarter?

In its 2026-02-25 report, RXST posted EPS of -0.22 USD versus a -0.3347 USD estimate — a beat of 34.3%.

What is RXST's earnings track record?

Over the last 4 reported quarters with consensus data, RXST beat estimates 4 times (100%).

What is RXST's current P/E ratio and EPS?

RXST trades at a trailing P/E of -4.77 on trailing EPS of -1.1290581466034928 USD.

What do analysts rate RXST?

Analyst consensus is "Hold" across 12 ratings (0 strong buy, 3 buy, 7 hold, 2 sell, 0 strong sell). Average 12-month price target: 8.75 USD.